reports
Correction to Company announcement – No. 23 / 2024
Correction to Company announcement – No. 23 / 2024 Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that mem...
Zealand Pharma launches long-term incentive programs for Zealand’s Boa...
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive prog...
Total number of shares and voting rights in Zealand Pharma at March 31...
Total number of shares and voting rights in Zealand Pharma at March 31, 2024 Company announcement – No. 21 / 2024 Total number of shares and voting rights in Zealand Pharma at March 31, 2024 Copenhagen, Denmark, March 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar mon...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 20 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received informa...
Zealand Pharma Increases its Share Capital as a Consequence of Exercis...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Company announcement – No. 19 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 32,808 divided into 32,808 new shares with a nominal value of DKK 1 each....
Zealand Pharma major shareholder announcement: Van Herk Investments
Zealand Pharma major shareholder announcement: Van Herk Investments Company announcement – No. 18 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 21 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 21 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 20 March 2024, Van ...
Zealand Pharma's Annual General Meeting 2024
Zealand Pharma's Annual General Meeting 2024 Company announcement – No. 17 / 2024 Zealand Pharma's Annual General Meeting 2024 Copenhagen, March 20, 2024 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2024 as a partly electronic and partly physical general meeting (hybrid meeting). At the meeting, all proposals presented to the General Meeting were adopted. The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and Zealand's audited Annual Report for 2023 was ap...
Zealand Pharma major shareholder announcement: Polar Capital
Zealand Pharma major shareholder announcement: Polar Capital Company announcement – No. 16 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 19 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 18 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 15 March 2024, Polar Capital ho...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 15 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received...
New Employee Elected Directors to the Board of Zealand Pharma A/S
New Employee Elected Directors to the Board of Zealand Pharma A/S Company announcement – No. 14 / 2024 New Employee Elected Directors to the Board of Zealand Pharma A/S Copenhagen, Denmark, March 13, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78). The employees of Zealand Pharma A/S have elected the following employee representatives and alternates for the Company’s Board of Directors: Employee representatives: Frederik Beck (re-elected)Anneline Nansen (re-elected)Ludovic Otterbein (newly elected) Adam Nygaard (newly elected) As...
Zealand Pharma AS: 1 director
A director at Zealand Pharma AS sold 1,000 shares at 739.000DKK and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 13 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 8, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received ...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 12 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 5, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercis...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Company announcement – No. 11 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 5, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 102,581 divided into 102,581 new shares with a nominal value of DKK 1 each. The increa...
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Co...
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference Press release – No. 3 / 2023 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, Chief Executive Officer, will present at TD Cowen’s 44th Annual Health Care Conference in Boston on Monday, March 4 at 1:30 – 2:00 p.m. ET (7:30 – 8:00 ...
Zealand Pharma convenes its Annual General Meeting 2024
Zealand Pharma convenes its Annual General Meeting 2024 Company Announcement – No. 10 / 2024 Zealand Pharma convenes its Annual General Meeting 2024 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Wednesday, March 20, 2024 at 3:00 pm (CEST) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting). ...
Zealand Pharma Announces Financial Results for the Full Year 2023
Zealand Pharma Announces Financial Results for the Full Year 2023 Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a solid financial position Positive results achieved for petrelintide in 6-week Phase 1 trial and clinical advancement of dapiglutide and petrelintide towards obesity data readouts in 2024Positive results announced in Boehringer Ingelheim Phase 2 clinical trials for survodutide in obesity and global Phase 3 clinical program in obesi...
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 tria...
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its pri...
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to p...
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on February 27, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the...
Total number of shares and voting rights in Zealand Pharma at January ...
Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Company announcement – No. 7 / 2024 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Copenhagen, Denmark, January 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar mon...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.